Belinostat
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BELINOSTAT |
|---|---|
| Type | Drug |
| Aliases | BeleodaqБелінoстат |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AITL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Pan-HDAC inhibitor (hydroxamic acid) |
|---|---|
| Mechanism | Pan-histone deacetylase (HDAC) inhibitor — increases acetylation of histones and non-histone proteins, derepressing tumor-suppressor genes, blocking cell-cycle progression, inducing apoptosis. Active in T-cell lymphomas with epigenetic dysregulation (TFH-cell origin, TET2/IDH2/DNMT3A mutations) — particularly AITL and PTCL NOS. |
| Typical dosing | 1000 mg/m² IV once daily on days 1-5 of each 21-day cycle, until progression or unacceptable toxicity |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
BELIEF trial (O'Connor 2015): r/r PTCL (incl AITL, PTCL NOS, ALCL, enteropathy-associated, hepatosplenic) — ORR 26%, CR 11%, median DOR 13.6 mo. FDA-approved for r/r PTCL. AITL subset response higher than PTCL NOS subset (likely TFH biology + epigenetic dependence). Major UA access barrier: not registered + not EMA-approved.
Used By
Regimens
REG-BELINOSTAT-PTCL- Belinostat IV days 1-5 q21d (BELIEF schedule) — r/r PTCL incl AITL